- Home
- AIRS vs RIGL Comparison
AIRS vs RIGL Comparison
Compare AIRS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | RIGL |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 537.6M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AIRS | RIGL |
|---|---|---|
| Price | $1.95 | $42.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.75 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 630.4K | 552.3K |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | $157,554,000.00 | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | $2.55 | $0.22 |
| P/E Ratio | ★ N/A | $6.91 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $1.53 | $15.50 |
| 52 Week High | $12.00 | $52.24 |
Technical Indicators
Market Signals| Indicator | AIRS | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 22.66 | 50.92 |
| Support Level | $1.94 | $41.54 |
| Resistance Level | $2.24 | $44.85 |
| Average True Range (ATR) | 0.22 | 1.73 |
| MACD | 0.12 | -0.28 |
| Stochastic Oscillator | 0.42 | 57.97 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.